Emerald Mutual Fund Advisers Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-284,657	Closed	-$23.8M	–	236
2024 Q4	$23.8M	Sell	284,657 -50,016	-15%	-$4.11M	1.45%	15
2024 Q3	$24.5M	Buy	334,673 +20,622	+7%	+$1.55M	1.27%	25
2024 Q2	$21.5M	Buy	314,051 +1,920	+0.6%	+$133K	1.13%	31
2024 Q1	$21.6M	Buy	312,131 +31,542	+11%	+$2.17M	1.12%	30
2023 Q4	$20.1M	Sell	280,589 -30,849	-10%	-$1.77M	1.06%	31
2023 Q3	$16.2M	Buy	311,438 +34,935	+13%	+$2.04M	0.98%	37
2023 Q2	$17.5M	Buy	+276,503	New	+$17.2M	0.95%	44

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's ITCI Position: Q1 2025 in Review

Emerald Mutual Fund Advisers Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 284,657 shares — an estimated $23.8M sold.

Emerald Mutual Fund Advisers Trust first reported a position in ITCI in Q2 2023 and held it in 7 quarters. The position peaked at $24.5M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Emerald Mutual Fund Advisers Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 284,657 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $23.8M.
Emerald Mutual Fund Advisers Trust first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 7 quarters.
Emerald Mutual Fund Advisers Trust's Intra-Cellular Therapies Inc. position peaked at $24.5M in Q3 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2025, filed 1 May 2025.